bluuebunny/crossref_metadata_2025 huggingface dataset:
Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Authors: Allan John N. , Flinn Ian W. , Siddiqi Tanya , Ghia Paolo , Tam Constantine S. , Kipps Thomas J. , Barr Paul M. , Elinder Camburn Anna , Tedeschi Alessandra , Badoux Xavier C. , Jacobs Ryan , Kuss Bryone J. , Trentin Livio , Zhou Cathy , Szoke Anita , Abbazio Christopher , Wierda William G.
Published: June 2023

AbstractPurpose:
The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax in patients with high-risk genomic features [del(17p), TP53 mutation, and/or unmutated immunoglobulin heavy chain (IGHV)] in CAPTIVATE.
Patients and Methods:
Patients received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). FD cohort patients (n = 159) received no further treatment. Forty-three MRD cohort patients with confirmed undetectable MRD (uMRD) after 12 cycles of ibrutinib plus venetoclax received randomized placebo treatment.
Results:
Of 195 patients with known status of genomic risk features at baseline, 129 (66%) had ≥1 high-risk feature. Overall response rates were >95% regardless of high-risk features. In patients with and without high-risk features, respectively, complete response (CR) rates were 61% and 53%; best uMRD rates: 88% and 70% (peripheral blood) and 72% and 61% (bone marrow); 36-month progression-free survival (PFS) rates: 88% and 92%. In subsets with del(17p)/TP53 mutation (n = 29) and unmutated IGHV without del(17p)/TP53 mutation (n = 100), respectively, CR rates were 52% and 64%; uMRD rates: 83% and 90% (peripheral blood) and 45% and 80% (bone marrow); 36-month PFS rates: 81% and 90%. Thirty-six–month overall survival (OS) rates were >95% regardless of high-risk features.
Conclusions:
Deep, durable responses and sustained PFS seen with fixed-duration ibrutinib plus venetoclax are maintained in patients with high-risk genomic features, with similar PFS and OS to those without high-risk features.
Supplemental Table 1 from Risk Factors for Early-onset Sporadic Colorectal Cancer in Male Veterans
Authors: Imperiale Thomas F. , Myers Laura J. , Barker Barry C. , Larson Jason , Stump Timothy E. , Daggy Joanne K.
Published: June 2023

Supplemental Table 1: Contains descriptive data for all candidate variables in cases and controls
Supplemental Methods 1 from Risk Factors for Early-onset Sporadic Colorectal Cancer in Male Veterans
Authors: Imperiale Thomas F. , Myers Laura J. , Barker Barry C. , Larson Jason , Stump Timothy E. , Daggy Joanne K.
Published: June 2023

Supplemental Methods 1: Contains details pertaining to data analysis
Suppl. Table 7 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

Other DDR pathways in inflammation and cancer
Suppl. Table 6 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

DDR signaling and inflammation in cancer
Suppl. Table 5 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

PARP signaling and inflammation in cancer
Suppl. Table 4 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

HR and inflammation in cancer
Suppl. Table 3 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

NHEJ and inflammation in cancer
Suppl. Table 2 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

MMR and inflammation in cancer
Suppl. Table 1 from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

BER and inflammation in cancer
Supplementary Table S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

List of major molecular profiling platforms included in the cohort
Supplementary Table S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Multivariable analysis - progression-free survival
Supplementary Table S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Baseline Patient Characteristics – Cohort B
Supplementary Table S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Baseline Patient Characteristics – Cohort A
Supplementary Table S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Baseline Patient Characteristics – Overall Cohort
Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NGS panel providing coverage for all 3 genes were included in this analysis.
Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for all patients evaluable for these co-alterations; survival outcomes according to ALK, ROS1, NTRK1-3 co-mutation status in C) all mutation-evaluable patients, and D) limiting the analysis to the KSC WT population.
Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
Supplementary Figure S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Progression-free survival (left) and overall survival (right) according to TP53 co-mutation status in A) overall cohort, B) cohort A, and C) cohort B.
Supplementary Figure S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors in the overall study cohort.
Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain metastases prior to starting KRAS G12Ci; C) Survival outcomes according to PD-L1 status (TPS: tumor proportion score); D) survival outcomes in patients with or without prior immune checkpoint inhibitor therapy.
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Authors: Negrao Marcelo V. , Araujo Haniel A. , Lamberti Giuseppe , Cooper Alissa J. , Akhave Neal S. , Zhou Teng , Delasos Lukas , Hicks J. Kevin , Aldea Mihaela , Minuti Gabriele , Hines Jacobi , Aredo Jacqueline V. , Dennis Michael J. , Chakrabarti Turja , Scott Susan C. , Bironzo Paolo , Scheffler Matthias , Christopoulos Petros , Stenzinger Albrecht , Riess Jonathan W. , Kim So Yeon , Goldberg Sarah B. , Li Mingjia , Wang Qi , Qing Yun , Ni Ying , Do Minh Truong , Lee Richard , Ricciuti Biagio , Alessi Joao Victor , Wang Jing , Resuli Blerina , Landi Lorenza , Tseng Shu-Chi , Nishino Mizuki , Digumarthy Subba R. , Rinsurongkawong Waree , Rinsurongkawong Vadeerat , Vaporciyan Ara A. , Blumenschein George R. , Zhang Jianjun , Owen Dwight H. , Blakely Collin M. , Mountzios Giannis , Shu Catherine A. , Bestvina Christine M. , Garassino Marina Chiara , Marrone Kristen A. , Gray Jhanelle E. , Patel Sandip Pravin , Cummings Amy L. , Wakelee Heather A. , Wolf Juergen , Scagliotti Giorgio Vittorio , Cappuzzo Federico , Barlesi Fabrice , Patil Pradnya D. , Drusbosky Leylah , Gibbons Don L. , Meric-Bernstam Funda , Lee J. Jack , Heymach John V. , Hong David S. , Heist Rebecca S. , Awad Mark M. , Skoulidis Ferdinandos
Published: June 2023

Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
Data from The DNA Damage Response and Inflammation in Cancer
Authors: Klapp Vanessa , Álvarez-Abril Beatriz , Leuzzi Giuseppe , Kroemer Guido , Ciccia Alberto , Galluzzi Lorenzo
Published: June 2023

Abstract
Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple components of the DNA damage response (DDR) operate as bona fide tumor suppressor proteins by preserving genomic stability, eliciting the demise of cells with unrepairable DNA lesions, and engaging cell-extrinsic oncosuppression via immunosurveillance. That said, DDR sig­naling can also favor tumor progression and resistance to therapy. Indeed, DDR signaling in cancer cells has been consistently linked to the inhibition of tumor-targeting immune responses. Here, we discuss the complex interactions between the DDR and inflammation in the context of oncogenesis, tumor progression, and response to therapy.
Significance:
Accumulating preclinical and clinical evidence indicates that DDR is intimately connected to the emission of immunomodulatory signals by normal and malignant cells, as part of a cell-extrinsic program to preserve organismal homeostasis. DDR-driven inflammation, however, can have diametrically opposed effects on tumor-targeting immunity. Understanding the links between the DDR and inflammation in normal and malignant cells may unlock novel immunotherapeutic paradigms to treat cancer.
Supplementary Data from T cell–Mediated Development of Stromal Fibroblasts with an Immune-Enhancing Chemokine Profile
Authors: Yan Ran , Moresco Philip , Gegenhuber Bruno , Fearon Douglas T.
Published: June 2023

Figure S1, S2, S3
Data from T cell–Mediated Development of Stromal Fibroblasts with an Immune-Enhancing Chemokine Profile
Authors: Yan Ran , Moresco Philip , Gegenhuber Bruno , Fearon Douglas T.
Published: June 2023

Abstract
Stromal fibroblasts reside in inflammatory tissues that are characterized by either immune suppression or activation. Whether and how fibroblasts adapt to these contrasting microenvironments remains unknown. Cancer-associated fibroblasts (CAF) mediate immune quiescence by producing the chemokine CXCL12, which coats cancer cells to suppress T-cell infiltration. We examined whether CAFs can also adopt an immune-promoting chemokine profile. Single-cell RNA sequencing of CAFs from mouse pancreatic adenocarcinomas identified a subpopulation of CAFs with decreased expression of Cxcl12 and increased expression of the T cell–attracting chemokine Cxcl9 in association with T-cell infiltration. TNFα and IFNγ containing conditioned media from activated CD8+ T cells converted stromal fibroblasts from a CXCL12+/CXCL9– immune-suppressive phenotype into a CXCL12–/CXCL9+ immune-activating phenotype. Recombinant IFNγ and TNFα acted together to augment CXCL9 expression, whereas TNFα alone suppressed CXCL12 expression. This coordinated chemokine switch led to increased T-cell infiltration in an in vitro chemotaxis assay. Our study demonstrates that CAFs have a phenotypic plasticity that allows their adaptation to contrasting immune tissue microenvironments.
Data from Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Authors: Desai Poonam N. , Wang Bofei , Fonseca Andre , Borges Pamella , Jelloul Fatima Zahra , Reville Patrick K. , Lee Eric , Ly Christopher , Basi Akshay , Root Jessica , Baran Natalia , Post Sean M. , Deng Qing , Sun Hanxiao , Harmanci Arif O. , Burks Jared K. , Gomez Javier A. , DiNardo Courtney D. , Daver Naval G. , Alatrash Gheath , Konopleva Marina , Green Michael R. , Antunes Dinler A. , Futreal Andrew , Hao Dapeng , Abbas Hussein A.
Published: June 2023

Abstract
Comprehensive investigation of CD8+ T cells in acute myeloid leukemia (AML) is essential for developing immunotherapeutic strategies beyond immune checkpoint blockade. Herein, we performed single-cell RNA profiling of CD8+ T cells from 3 healthy bone marrow donors and 23 newly diagnosed (NewlyDx) and 8 relapsed/refractory (RelRef) patients with AML. Cells coexpressing canonical exhaustion markers formed a cluster constituting <1% of all CD8+ T cells. We identified two effector CD8+ T-cell subsets characterized by distinct cytokine and metabolic profiles that were differentially enriched in NewlyDx and RelRef patients. We refined a 25-gene CD8-derived signature correlating with therapy resistance, including genes associated with activation, chemoresistance, and terminal differentiation. Pseudotemporal trajectory analysis supported enrichment of a terminally differentiated state in CD8+ T cells with high CD8-derived signature expression at relapse or refractory disease. Higher expression of the 25-gene CD8 AML signature correlated with poorer outcomes in previously untreated patients with AML, suggesting that the bona fide state of CD8+ T cells and their degree of differentiation are clinically relevant. Immune clonotype tracking revealed more phenotypic transitions in CD8 clonotypes in NewlyDx than in RelRef patients. Furthermore, CD8+ T cells from RelRef patients had a higher degree of clonal hyperexpansion associated with terminal differentiation and higher CD8-derived signature expression. Clonotype-derived antigen prediction revealed that most previously unreported clonotypes were patient-specific, suggesting significant heterogeneity in AML immunogenicity. Thus, immunologic reconstitution in AML is likely to be most successful at earlier disease stages when CD8+ T cells are less differentiated and have greater capacity for clonotype transitions.
Supplementary Figure S4 from Multi-institutional prognostic modelling in head and neck cancer:
evaluating impact and generalizability of deep learning and
radiomics
Authors: Kazmierski Michal , Welch Mattea , Kim Sejin , McIntosh Chris , Rey-McIntyre Katrina , Huang Shao Hui , Patel Tirth , Tadic Tony , Milosevic Michael , Liu Fei-Fei , Ryczkowski Adam , Kazmierska Joanna , Ye Zezhong , Plana Deborah , Aerts Hugo JWL , Kann Benjamin H , Bratman Scott V. , Hope Andrew J , Haibe-Kains Benjamin
Published: June 2023

Model performances across permutations by clinical and imaging variables.
TABLE 2 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Adverse events
Supplementary Figure S3 from Multi-institutional prognostic modelling in head and neck cancer:
evaluating impact and generalizability of deep learning and
radiomics
Authors: Kazmierski Michal , Welch Mattea , Kim Sejin , McIntosh Chris , Rey-McIntyre Katrina , Huang Shao Hui , Patel Tirth , Tadic Tony , Milosevic Michael , Liu Fei-Fei , Ryczkowski Adam , Kazmierska Joanna , Ye Zezhong , Plana Deborah , Aerts Hugo JWL , Kann Benjamin H , Bratman Scott V. , Hope Andrew J , Haibe-Kains Benjamin
Published: June 2023

Model performances across permutations by clinical (EMR) variables.
TABLE 1 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Patient characteristics, treatment, and OS outcomes
Supplementary Figure S1 from Multi-institutional prognostic modelling in head and neck cancer:
evaluating impact and generalizability of deep learning and
radiomics
Authors: Kazmierski Michal , Welch Mattea , Kim Sejin , McIntosh Chris , Rey-McIntyre Katrina , Huang Shao Hui , Patel Tirth , Tadic Tony , Milosevic Michael , Liu Fei-Fei , Ryczkowski Adam , Kazmierska Joanna , Ye Zezhong , Plana Deborah , Aerts Hugo JWL , Kann Benjamin H , Bratman Scott V. , Hope Andrew J , Haibe-Kains Benjamin
Published: June 2023

Patient selection and data curation process.
Supplementary Table S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Count of CD8+T cell and iNKT cell products in each course
Supplementary Data from Multi-institutional prognostic modelling in head and neck cancer:
evaluating impact and generalizability of deep learning and
radiomics
Authors: Kazmierski Michal , Welch Mattea , Kim Sejin , McIntosh Chris , Rey-McIntyre Katrina , Huang Shao Hui , Patel Tirth , Tadic Tony , Milosevic Michael , Liu Fei-Fei , Ryczkowski Adam , Kazmierska Joanna , Ye Zezhong , Plana Deborah , Aerts Hugo JWL , Kann Benjamin H , Bratman Scott V. , Hope Andrew J , Haibe-Kains Benjamin
Published: June 2023

Supplementary Data of figures/tables
Supplementary Table S1 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Representativeness of Study Participants
Supplementary Figure S5 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Proliferation curve of iNKT cells of P001 (A) and P002 (B) during expansion ex vivo. Curves representing iNKT cells expanded in later courses is shown in darker color.
Supplementary Figure S4 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Heatmap shows the frequencies of the top 50 TCR clones in CD8+T cells in cell products pre-infusion and PBMCs four weeks post infusion. Scale bar, %.
Supplementary Figure S3 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Gating strategy to detect CD4+ T, CD8+ T, B and NK cells by flow cytometry. Only living cells were included in the analysis (A). Changing in percentages of CD4+ T, CD8+ T, B, and NK cells during treatment are shown in panels B, C, D and E respectively.
Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Change of tumor markers recorded over time during treatment.
FIGURE 4 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Clinical response and OS data. A, Waterfall plot showing best overall change in sum of diameter of tumor lesions for each patient. Change in sum of tumor diameters by RECIST is compared with baseline. Representative CT images of patient 001 and patient 002 with PR of the sum of lesions are shown in B and C, respectively. D, Kaplan–Meier estimate of OS of all 9 patients (black), patients with elevated IFNγ-secreting cells responding to α-Galcer (pink) and the others (blue).
FIGURE 3 from Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1+CD8+ T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
Authors: Wang Jing , Cheng Xiaobo , Jin Yanling , Xia Bili , Qin Ran , Zhang Wei , Hu Huiliang , Mao Xiaoting , Zhou Liting , Yan Jia , Zhang Xiaoyan , Xu Jianqing
Published: June 2023

Clinical records and detections. A, The body temperature of patients recorded each hour for 20 hours after cell infusion. All the records in 59 courses are included here in gray. The mean temperature in each timepoint is shown in black bold. Changes in tumor markers CA19-9 in serum during cellular therapy were shown in B. Impact of cell infusion on the cytokines in serum and key populations of lymphocytes in PBMCs. Quantification of Th1/2/17 cytokines in plasma after cell infusion were analyzed by CBA. All results are displayed in C. Change of IL6 in serum over time are shown in D, on which red dots indicated elevated IL6 levels post infusion. Change of IL6 (left) and IL17A (right) during treatment are shown in E. Changing percentage of CD4+ T, CD8+ T, B, and NK cells during treatment are assessed by flow cytometry, and data relative to baseline are shown in F, G, H, and I, respectively. Changes in number of IFNγ-secreting cells responding to α-Galcer were also recorded using ELISPOT and are shown in J with increased IFNγ-secreting cells responding to α-Galcer in some patients (solid) and not in others (dotted).
Enhanced Learning Continuity Framework Using Online Teaching as Alternative Delivery Modality
Authors: Hermosisima Mary Chandra R. , Mobo Froilan D. , Cutillas Anesito L.
Published: June 2023

This study explores the integration of technology platforms in online modular learning and proposes an enhanced learning continuity framework using online teaching as an alternative delivery modality. The study captures participants’ experiences related to online modular education through surveys by employing a qualitative approach. The findings demonstrate that integrating technological platforms enhances learning continuity. Online teaching offers flexible and accessible learning experiences, fostering effective teaching and learning. The study emphasizes the significance of comprehensive technical infrastructure, blended learning approaches, pedagogical and learner support services, continuous assessment, and a healthy learning environment in crafting the framework. The framework emphasizes robust technological infrastructure, training programs, blended learning approaches, pedagogical support, diverse assessment strategies, and a healthy learning environment by addressing challenges like the digital divide, technical difficulties, and lack of face-to-face interaction, flexibility, adaptability, and continuous evaluation are emphasized to address specific institutional and learner needs. Implementing the framework requires collaboration among educational institutions, policymakers, and communities to create inclusive online learning environments. Efforts should be made to ensure equitable access to reliable internet connections, support disadvantaged learners, and foster creativity through interactive activities. Monitoring and evaluation play a vital role in tracking progress and making informed decisions for improvement. This study provides a foundation for institutions to develop an enhanced learning continuity framework using online teaching. By optimizing the benefits of online modular learning while addressing challenges, the framework promotes effective teaching and learning in the online education landscape.
Scenario- Based Learning Approach for Enhancing the Critical Thinking Skills of Grade 9 Students in Araling Panlipunan
Authors: Joaquin Lyn L. , Hermosa Jherwin P.
Published: June 2023

This study examined the efficacy of Scenario- Based Learning (SBL) Approach for enhancing the Critical thinking skills of Grade 9 students in Araling Panlipunan. Scenario- Based Learning Approach is a student centred approach in Araling Panlipunan and suited to the 21st century learners. Thus, this descriptive quasi-experimental research design determined the cause and effect of SBL approach to the critical thinking skills of 40 Grade 9 students of Col. Lauro D. Dizon Memorilal Integrated High School. The results were analysed using mean and standard deviation, t-test and Pearson-r correlation.  The study revealed that using SBL approach, students can become more involved, motivated, and develop their real-world skills. Application of SBL approach had great impact in the learning process.  Moreover, there was a significant difference in the responses of learners in the pre-test and posttest. It means that the quality and content of SBL approach has positive impact on the learning process in critical thinking skills.  This approach become more effective in critical thinking skills as learners had been able to remember, reason and pay attention to SBL approach video lesson. In addition, usage of technology improved learning. The opportunities for teaching with audio visual lessons are ideally adapted to the learners’ environment. Thus, learning scenario encourages students to think about what they have learned.
Evaluation of the Implementation of Crime Prevention Strategies of the Philippine National Police in Ormoc City, Leyte in the Context of the Covid-19 Pandemic
Authors: Molas Nancy Hernando , Hernando Loela Elisan , Mallorca Hessimae Sanoria , Ceniza Marie Regulacion , Malang Bernandino P. , Vigonte Florinda G.
Published: June 2023

The COVID-19 Pandemic had made the Philippines to face various expanding crime rates which became a valuable issue in the country. These wrongdoings had operationally pushed the Philippine National Police to see and assess different crime activities that had been concurring consistently. This made the PNP to established community public security which then is called to be crime prevention strategies. This confronts the transition of different conflicting state including actions that inflicts harm to the populace. However, the known implemented strategies were not observed whether these promotes consistent advantage security or implementation were not addressed properly. Therefore, this study aims to determine the evaluation of the implementation of crime prevention strategies of the Philippine National Police in Ormoc City, Leyte in the Context of the COVID-19 Pandemic. A descriptive quantitative was used in purposive sampling was employed to obtain the 125 respondents of the study mainly PNP personnel and barangay captain. A self-constructed questionnaire with 4-point Likert scale has undergone a pilot study among 25 known respondents wherein the actual run was done through online survey. The result had shown that indicators including the crime prevention activities as to prevention strategies shows no significant differences. However, sustainability of the strategies establishes relationship with the demographic profile. Therefore, the study had concluded that the null hypothesis must be accepted which pertains that the strategies of the PNP towards crime prevention is not highly significant with the demographic profile.
Disparities in Postdischarge Ambulatory Care Follow‐Up Among Medicaid Beneficiaries With Diabetes, Hospitalized for Heart Failure
Authors: Khodneva Yulia , Levitan Emily B. , Arora Pankaj , Presley Caroline A. , Oparil Suzanne , Cherrington Andrea L.
Published: June 2023

Background

Ambulatory follow‐up for all patients with heart failure (HF) is recommended within 7 to 14 days after hospital discharge to improve HF outcomes. We examined postdischarge ambulatory follow‐up of patients with comorbid diabetes and HF from a low‐income population in primary and specialty care.

Methods and Results

Adults with diabetes and first hospitalizations for HF, covered by Alabama Medicaid in 2010 to 2019, were included and the claims analyzed for ambulatory care use (any, primary care, cardiology, or endocrinology) within 60 days after discharge using restricted mean survival time regression and negative binomial regression. Among 9859 Medicaid‐covered adults with diabetes and first hospitalization for HF (mean age, 53.7 years; SD, 9.2 years; 47.3% Black; 41.8% non‐Hispanic White; 10.9% Hispanic/Other [Other included non‐White Hispanic, American Indian, Pacific Islander and Asian adults]; 65.4% women, 34.6% men), 26.7% had an ambulatory visit within 0 to 7 days, 15.2% within 8 to 14 days, 31.3% within 15 to 60 days, and 26.8% had no visit; 71% saw a primary care physician and 12% a cardiology physician. Black and Hispanic/Other adults were less likely to have any postdischarge ambulatory visit (
P
<0.0001) or the visit was delayed (by 1.8 days,
P
=0.0006 and by 2.8 days,
P
=0.0016, respectively) and were less likely to see a primary care physician than non‐Hispanic White adults (adjusted incidence rate ratio, 0.96 [95% CI, 0.91–1.00] and 0.91 [95% CI, 0.89–0.98]; respectively).

Conclusions

More than half of Medicaid‐covered adults with diabetes and HF in Alabama did not receive guideline‐concordant postdischarge care. Black and Hispanic/Other adults were less likely to receive recommended postdischarge care for comorbid diabetes and HF.